Relay Therapeutics, Inc. Common Stock (RLAY) — Analysis Summary
Relay Therapeutics, Inc. Common Stock (RLAY) has a market cap of $3.26B with year-over-year revenue growth of +53.4%. Net margin stands at -1800.6%. The stock trades at a P/E ratio of -12.0.
Key Takeaways
- Revenue changed +53.4% year-over-year
- Net margin of -1800.6%
- P/E ratio of -12.0
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, RLAY posted revenue growth of +53.4% and trades at a P/E of -12.0.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.